Skip to Content

Jentadueto Approval History

FDA Approved: Yes (First approved January 30, 2012)
Brand name: Jentadueto
Generic name: linagliptin and metformin hydrochloride
Dosage form: Tablets
Company: Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly
Treatment for: Diabetes, Type 2

Jentadueto (linagliptin and metformin) is a dipeptidyl peptidase-4 (DPP-4) inhibitor and biguanide combination product indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Development History and FDA Approval Process for Jentadueto

DateArticle
May 31, 2016Approval FDA Approves Once-Daily Jentadueto XR (linagliptin and metformin hydrochloride extended-release) for Type 2 Diabetes
Feb  1, 2012Approval FDA Approves Jentadueto (linagliptin/metformin hydrochloride) for the Treatment of Adult Patients with Type 2 Diabetes

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide